20: dhps Mutations and SP Protection

Mousa A et al., Nature Communications - Pooled analysis of seven therapeutic efficacy trials (1639 participants, 12 African sites) quantifies how dhps resistance genotypes shorten the duration of protection from sulfadoxine-pyrimethamine (SP) and maps predicted chemoprevention impact across Africa. Key terms: sulfadoxine-pyrimethamine, dhps mutations, chemoprevention, malaria, genomic surveillance. Study Highlights:The authors pooled individual-level data from seven trials (1639 participants) and used a Bayesian multi-strain Weibull survival model to estimate genotype-specific durations of SP protection while accounting for site-level transmission. Mean protection against sulfadoxine-susceptible dhps AKA parasites was longest (≈55.7 days), intermediate for dhps GKA (≈33.9 days), and substantially shorter for dhps GEA (≈10.7 days) and dhps GEG (≈11.7 days). SP combined with amodiaquine (SPAQ) showed markedly longer protection against GEA in the available data (≈42.5 days). The study produced maps and a web tool to predict local SP protective efficacy using genomic surveillance inputs. Conclusion:dhps resistance mutations substantially reduce the duration of SP post-treatment protection; integrating genotype surveillance into policy can guide where SP-based chemoprevention is likely to remain effective and where alternatives such as SPAQ should be considered. QC:This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-05-16. QC Scope:- article metadata and core scientific claims from the narration- excludes analogies, intro/outro, and music QC Summary:- factual score: 10/10- metadata score: 10/10- supported core claims: 6- claims flagged for review: 0- metadata checks passed: 4- metadata issues found: 0 Metadata Audited:- article_doi- article_title- article_journal- license Factual Items Audited:- SP protection duration varies by dhps genotype; longest against sulfadoxine-susceptible AKA parasites (~55.7–56 days) and shorter for GKA (~33.9 days), GEA (~10.7 days), and GEG (~- SPAQ (SP + amodiaquine) provides markedly longer protection against GEA than SP alone, with ~42.5 days versus ~10.7 days for SP alone.- Validation with IPTi trials showed model predictions closely matched observed reinfection rates, supporting generalizability of genotype-specific protection estimates.- A web-based tool was developed to predict SP protective efficacy based on local dhps genotype frequencies, enabling policy tailoring.- Across sub-Saharan Africa, 30-day protective efficacy against infection varies from about 59% to 92%, with a mean of approximately 4.7 clinical malaria cases averted per 100 childr- Policy implications: strategies should be tailored to local resistance patterns, using molecular surveillance to guide where SP is effective and where alternatives (e.g., SPAQ) sho QC result: Pass.